Overview

Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr

Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
Double blind study to assess versus placebo the efficacy of SSR149744C for the conversion of atrial fibrillation/flutter to sinus rhythm at the time of the planned electrical cardioversion.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi